Tracer library / [213Bi]Bi-3p-C-NETA-ePSMA-16

[213Bi]Bi-3p-C-NETA-ePSMA-16

Radionuclide: Bi-213 t½ 45.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-targeting urea-based small molecule with NETA chelator (3p-C-NETA-ePSMA-16)
Target / mechanism: PSMA (prostate-specific membrane antigen) targeting PMID 37375829
Clinical application: Prostate cancer imaging and treatment PMID 37375829
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	94%	97.4 ± 2.4%	3p-C-NETA-ePSMA-16	37375829 2023 Pharmaceuticals (Basel) The synthesis of [213Bi]Bi-3p-C-NETA-ePSMA-16 was performed by reacting 213BiI52− (6–12 MBq) with 3p-C-NETA-ePSMA-16 (3 nmol, 300 µL, 10 µM) at 95 °C for 7 min - [213Bi]Bi-3p-C-NETA-ePSMA-16 was obtained with excellent RCC (94%, n = 1)

Need this precursor?We can point you to suppliers for [213Bi]Bi-3p-C-NETA-ePSMA-16, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37375829. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37375829: '3p-C-NETA-ePSMA-16 (3 nmol, 300 µL, 10 µM)'. Stage set/updated at stage 39 from PMID 37375829: 'Therapy studies with short-lived radionuclides such as 213Bi could further elucidate the therapeutic potential of 3p-C-NETA-ePSMA-16 as a radiotheranostic.'.